In the research and development and activity detection of antibody drugs, highly specific and stable detection tools are crucial. However, the inherent limitations of traditional polyclonal secondary antibodies have become a key bottleneck affecting data accuracy and research efficiency.
Four Core Challenges of Traditional Polyclonal Antibody
1. Specificity Ambiguity and Significant Background Interference: Polyclonal antibody is mixtures recognizing multiple epitopes, leading to a high risk of nonspecific binding and resulting in low signal-to-noise ratios in experimental results.
2. Significant Batch Variations and Difficulty in Data Comparison: The composition of polyclonal antibody from different animals and batches is uncontrollable, severely interfering with experimental reproducibility and data stability.
3. Over-Amplification of Signal, Obscuring True Activity: Multiple binding sites may cause nonlinear signal amplification, making it impossible to accurately quantify the true antibody-antigen binding strength.
4. Blindness to Novel Structures, Limited Applications: With the emergence of complex structures such as triple and polyclonal antibodies, traditional secondary antibodies interfere with result interpretation.
These challenges directly affect the accurate assessment of drug efficacy, affinity, and pharmacokinetic parameters, increasing the uncertainty and risk in research and development.
AlpVHHs: A Fundamental Solution Based on Recombinant Nanobody
To overcome the aforementioned challenges, AlpVHHs leveraging its unique yeast display platform, has developed a new generation of recombinant nanobody. Our products represent not simply improvements, but a systemic innovation in molecular design, production, and performance.
Fig: Schematic diagram of Human IgG structure and its recognizable domains
Today, we will introduce a revolutionary product—Anti-Human IgG (CH1 Fragment specific), AlpSdAbs VHH series products offer a variety of labeling options, including HRP, Biotin, PE, APC, iFluor488, iFluor594, and iFluor647, which can be used for accurate quantitative detection on platforms such as ELISA, WB, Flow Cyt, ICC/IF, and IP, meeting the needs of different experimental platforms and application scenarios.
Advantages of Anti-Human IgG (CH1 Fragment Specific) Recombinant Nano-Secondary Antibody in Detection
1. Precise CH1 Fragment Recognition: Clearly and specifically binds to the CH1 constant region, without interfering with Fab antigen recognition.
2. High Homogeneity: Monoclonal recombinant expression ensures a fully controllable production process, with near-zero batch-to-batch variation. This achieves long-term comparability and standardization of experimental data, supporting compliant drug applications.
3. Ultra-Low Background Interference: Nanobodies (VHH) naturally do not contain Fc fragments, fundamentally eliminating non-specific binding caused by Fc receptors. This makes them particularly suitable for techniques with stringent background requirements, such as flow cytometry and immunohistochemistry, yielding clearer results.
4. Definite Performance: The clone's sequence, affinity (Kd), and specificity are rigorously characterized and quality-controlled. Experimental results are highly predictable and interpretable, meeting the stringent requirements of drug development.
Empowering the Entire Antibody Drug Development Process
With these advantages, recombinant nanoparticles have become ideal tools for the following key stages:
1. Drug Activity and Affinity Assessment: Achieving precise quantification on platforms such as ELISA and SPR/BLI.
2. Pharmacokinetic Studies: Monitoring drug concentrations with high specificity and sensitivity in complex biological matrices.
3. Manufacturing Process Quality Control: Stably monitoring antibody concentration and integrity during purification and formulation.
4. Novel Drug Structure Detection: Highly supporting the development of cutting-edge molecules such as bispecific antibodies, nanobody drugs, and ADCs.
5. Multiplex Detection Development: Easily conjugated to different tags to construct flexible multiplex detection systems.
Case Study
1. Anti-Human IgG(CH1 Fragment specific), AlpSdAbs® VHH(HRP) (Code: 023-105-005)
2. Anti-Human IgG(CH1 Fragment specific), AlpSdAbs® VHH(PE) (Code:023-105-010)
3. Anti-Human IgG(CH1 Fragment specific), AlpSdAbs® VHH(APC) (Code: 023-105-011)
AlpVHHs' recombinant nano-secondary antibody, through precise design concepts, industrialized production standards, and unique molecular morphology, systematically address the pain points of traditional polyclonal antibodies. They are not only superior diagnostic reagents but also key enabling tools for improving the quality, reproducibility, and efficiency of antibody drug development data, providing a solid foundation for the rapid and robust development of innovative drugs.
Product Catalog
Code | Description | Application |
023-105-010 | Flow Cyt | |
023-105-011 | Flow Cyt | |
023-105-007 | Anti-Human IgG(CH1 Fragment specific), AlpSdAbs® VHH(iFluor488 ×4) | WB,ELISA,ICC/IF,Flow Cyt |
023-105-008 | Anti-Human IgG(CH1 Fragment specific), AlpSdAbs® VHH(iFluor594 ×4) | WB,ELISA,ICC/IF,Flow Cyt |
023-105-009 | Anti-Human IgG(CH1 Fragment specific), AlpSdAbs® VHH(iFluor647 ×4) | WB,ELISA,ICC/IF,Flow Cyt |
023-105-004 | Anti-Human IgG(CH1 Fragment specific), AlpSdAbs® VHH(Biotin) | WB,ELISA,IP,Purification,BLI,SPR |
023-105-005 | WB,ELISA | |
023-405-001 | WB,ELISA | |
023-105-005 | WB,ELISA | |
023-405-001 | Anti-Human IgG(CH1 Fragment specific), AlpHcAbs® Goat antibody | WB,ICC/IF,ELISA,IP,Flow Cyt |
023-405-004 | Anti-Human IgG(CH1 Fragment specific), AlpHcAbs® Goat antibody(Biotin) | WB,ELISAIP |
023-405-005 | Anti-Human IgG(CH1 Fragment specific), AlpHcAbs® Goat antibody(HRP) | WB,ELISA |
